Compare Global X Lithium & Battery Tech ETF (LIT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Global X Lithium & Battery Tech ETF trades at $65 (market cap $1.45B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Global X Lithium & Battery Tech ETF is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 57 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LIT | MRVI | |
|---|---|---|
Market Cap | $1.45B | $972.90M |
Volume | 191,139 | 4,325,710 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $9.00 |
52-Week Low | $56.39 | $2.83 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $67.65, down 1.05% with bearish technical signals from moving averages and oscillators. The ETF faces headwinds from volatile lithium prices and oversupply concerns, though long-term prospects remain supported by EV adoption trends. Recent news highlights significant short interest reduction and China's ambitious 30% EV fleet target by 2030.
Outlook is cautious near-term due to technical weakness and commodity volatility, but structural EV growth offers recovery potential. Risks include lithium price swings and geopolitical trade tensions, while institutional sentiment shows mixed signals with recent short covering.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
